Literature DB >> 32271958

Ginsenoside 20(S)-Rg3 upregulates HIF-1α-targeting miR-519a-5p to inhibit the Warburg effect in ovarian cancer cells.

Jiaojiao Lu1,2, Hong Chen1,3, Fang He1,2, Yuanyi You1,2, Zhaozu Feng1,2, Wei Chen4, Xu Li1,2, Le Zhao1,2.   

Abstract

The Warburg effect, one of the metabolic hallmarks of cancer, is responsible for rapid energy production through a high rate of aerobic glycolysis. Ginsenoside 20(S)-Rg3 antagonizes the Warburg effect in ovarian cancer cells by upregulating some microRNAs, including miR-519a-5p, that target key enzymes involved in aerobic glycolysis. How 20(S)-Rg3-upregulated miR-519a-5p influences the Warburg effect in ovarian cancer cells remains poorly defined, however. Here we report that while overexpression of miR-519a-5p in ovarian cancer cells inhibited the Warburg effect, inhibition of miR-519a-5p negated the suppressive action of 20(S)-Rg3 against the Warburg effect as evidenced by a decrease in glucose consumption, lactate production and HK2 expression. We identified HIF-1α as a direct target of miR-519a-5p via luciferase reporter assays and demonstrated the counteraction by overexpressed HIF-1α of 20(S)-Rg3-suppressed Warburg effect. Further, 20(S)-Rg3 decreased DNMT3A-mediated DNA methylation in the promoter region of its precursor gene, leading to an increase in the level of miR-519a-5p. In conclusion, 20(S)-Rg3 upregulates miR-519a-5p via reducing DNMT3A-mediated DNA methylation to inhibit HIF-1α-stimulated Warburg effect in ovarian cancer.
© 2020 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Warburg effect; methylation; microRNA; ovarian cancer

Year:  2020        PMID: 32271958     DOI: 10.1111/1440-1681.13321

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

1.  [Ginsenoside 20(S)-Rg3 upregulates tumor suppressor VHL gene expression by suppressing DNMT3A-mediated promoter methylation in ovarian cancer cells].

Authors:  Lijie Wang; Xi Han; Xia Zheng; Yuanyuan Zhou; Huilian Hou; Wei Chen; Xu Li; Le Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

2.  LINC01234 regulates microRNA-27b-5p to induce the migration, invasion and self-renewal of ovarian cancer stem cells through targeting SIRT5.

Authors:  Fang Ke; Chenchen Ren; Zihan Zhai; Xiang Gao; Jing Wei; Yuanhang Zhu; Yunxiao Zhi
Journal:  Cell Cycle       Date:  2022-03-01       Impact factor: 5.173

3.  Ginsenoside Rg3 Prevents Oncogenic Long Noncoding RNA ATXN8OS from Inhibiting Tumor-Suppressive microRNA-424-5p in Breast Cancer Cells.

Authors:  Heejoo Kim; Hwee Won Ji; Hyeon Woo Kim; Sung Hwan Yun; Jae Eun Park; Sun Jung Kim
Journal:  Biomolecules       Date:  2021-01-18

Review 4.  The crosstalk between HIFs and mitochondrial dysfunctions in cancer development.

Authors:  Xingting Bao; Jinhua Zhang; Guomin Huang; Junfang Yan; Caipeng Xu; Zhihui Dou; Chao Sun; Hong Zhang
Journal:  Cell Death Dis       Date:  2021-02-26       Impact factor: 8.469

Review 5.  HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies.

Authors:  Xin Wang; Zhen-Wu Du; Tian-Min Xu; Xiao-Jun Wang; Wei Li; Jia-Li Gao; Jing Li; He Zhu
Journal:  Front Oncol       Date:  2021-12-24       Impact factor: 6.244

Review 6.  Noncoding RNAs in the Glycolysis of Ovarian Cancer.

Authors:  Chunmei Zhang; Ning Liu
Journal:  Front Pharmacol       Date:  2022-03-30       Impact factor: 5.810

Review 7.  Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches.

Authors:  Carla Navarro; Ángel Ortega; Raquel Santeliz; Bermary Garrido; Maricarmen Chacín; Néstor Galban; Ivana Vera; Juan Bautista De Sanctis; Valmore Bermúdez
Journal:  Pharmaceutics       Date:  2022-06-19       Impact factor: 6.525

Review 8.  Epigenetic Studies of Chinese Herbal Medicine: Pleiotropic Role of DNA Methylation.

Authors:  Wenqian Guo; Han Ma; Chong-Zhi Wang; Jin-Yi Wan; Haiqiang Yao; Chun-Su Yuan
Journal:  Front Pharmacol       Date:  2021-12-07       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.